The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 6, 2015, Pages 998-1000.e2

  Lucas, Mary ^a   Lee, Martin ^b   Oksenhendler, Eric ^c   Chapel, Helen ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN G; MESSENGER RNA; METHOTREXATE;

ALBUMIN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BRONCHIECTASIS; CORTICOSTEROID THERAPY; CYTOPENIA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; ENTEROPATHY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; PHENOTYPE; SPLENOMEGALY; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGY; PASSIVE IMMUNIZATION;

HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOLOGIC DEFICIENCY SYNDROMES;

EID: 84946403910     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.07.001     Document Type: Article

References (12)

1. Gouilleux-Gruart V., Chapel H., Chevret S., Lucas M., Malphettes M., Fieschi C., et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol 2013, 171:186-194.
2. Lucas M., Lee M., Lortan J., Lopez-Granados E., Misbah S., Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010, 125:1354-1360.
3. Litzman J. Influence of FCRN expression on lung decline and intravenous immunoglobulin catabolism in common variable immunodeficiency patients. Clin Exp Immunol 2014, 178:103-104.
4. Church J., Leibl H., Stein M., Melamed I., Rubenstsein E., Schneider L., et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 2006, 26:388-395. the US-PID-IGIV 10% -Study Group10.
5. Ballow M., Berger M., Bonilla F.A., Buckley R.H., Cunningham-Rundles C., Fireman P., et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex™, 10%). Vox Sang 2003, 84:202-210.
6. Ochs H., Pinciaro P. Octagam® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 2004, 24:309-314. the OCTAGAM study group.
7. Berger M., Rojavin M., Kiessling P., Zenkerb O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011, 139:133-141.
8. Orange J., Belohradsky B.H., Berger M., Borte M., Hagan J., Jolles S., et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012, 169:172-181.
9. Chapel H., Spickett G.P., Ericson D., Engl W., Eibl M.M., Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000, 2:94-100.
10. Freiberger T., Grodecká L., Ravcuková B., Kurecová B., Postránecká V., Vlcek J., et al. Association of FcRn expression with lung abnormalities and IVIG catabolism in patients with common variable immunodeficiency. Clin Immunol 2010, 136:419-425.
11. Chapel H., Lee M. Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism. J Clin Immunol 1992, 12:17-20.
12. Hodkinson J.P., Lucas M., Lee M., Harrison M., Lunn M.P., Chapel H. Therapeutic immunoglobulin should be dosed by clinical outcome rather than by body weight in obese patients. Clin Exp Immunol 2015, 181:179-187.